Description
Quick Facts
PE-22-28’s primary mechanism of action is believed to involve the selective inhibition of the TREK-1 potassium channel. TREK-1 channels are mechanosensitive ion channels widely expressed in the brain, particularly in areas associated with mood regulation (e.g., hippocampus, prefrontal cortex). By inhibiting TREK-1, PE-22-28 can lead to neuronal depolarization and increased neuronal excitability, which can enhance synaptic plasticity and signaling. Furthermore, research suggests that PE-22-28’s effects extend beyond TREK-1 inhibition to include:
- Neurotrophic Support: It has been shown to induce the production of brain-derived neurotrophic factor (BDNF), a crucial protein for neuronal survival, growth, differentiation, and synaptic plasticity. Increased BDNF levels are often associated with improved mood and cognitive function.
- Antidepressant-like Effects: By modulating neuronal excitability and promoting neurotrophic pathways, PE-22-28 is thought to contribute to rapid and sustained antidepressant effects observed in preclinical models.
- Neuroprotection: Its influence on neuronal health and resilience may confer neuroprotective benefits against various insults, including stress-induced neuronal damage.
- Depression and Mood Disorders: A major focus of research for its potential as a novel, fast-acting antidepressant, particularly for treatment-resistant depression, given its distinct mechanism from conventional antidepressants.
- Neurodegenerative Diseases: Explored for its neuroprotective and neurotrophic properties in conditions such as Alzheimer’s disease and Parkinson’s disease, where neuronal degeneration and synaptic dysfunction play key roles.
- Cognitive Function: Research into its ability to improve learning and memory, potentially through enhanced synaptic plasticity mediated by BDNF.
- Stress-Related Disorders: Investigations into its anxiolytic (anti-anxiety) effects and its potential to mitigate the neurological impact of chronic stress.
- Pain Management: Some exploratory research may delve into its potential analgesic properties due to its modulation of neuronal excitability.
Why Choose Peptide Chains for PE-22-28?
Peptide Chains provides high-purity PE-22-28 in bulk API quantities, essential for rigorous neuropharmacological and psychiatric research. Our PE-22-28 is meticulously synthesized and supplied in a stable, lyophilized format, ensuring optimal integrity, purity (typically ≥98%), and ease of reconstitution for your precise experimental protocols. We are committed to stringent quality control, including comprehensive analytical testing, to guarantee the exceptional purity, potency, and batch-to-batch consistency that is critical for reliable and reproducible results in studies focused on novel antidepressant therapies, neuroprotection, and the complex mechanisms of brain health and plasticity.
